Veraxa Biotech AG appointed Raju Willener as Chief Financial Officer and principal accounting officer, effective September 4, 2026. Mr. Willener brings over three decades of international experience in investment banking, corporate finance, and asset management, having previously served as CFO at Exentis Group AG. He succeeds Carl von Halem, who is thanked for his support. Veraxa Biotech AG operates in the biotechnology industry, developing next-generation antibody-based cancer therapies.

Veraxa Biotech AG announced the advancement of its bispecific antibody drug conjugate (bsADC) program VXA-222 into its next phase following a technical milestone in its collaboration with OmniAb, Inc. The program utilizes an "AND-gate" logic to target two different antigens on solid tumors. Veraxa Biotech AG is a biotechnology company focused on designing and developing next-generation antibody-based therapeutics.

Veraxa Biotech AG shareholders approved amendments to the Articles of Association at an Extraordinary General Meeting on July 24, 2026. Key changes include the introduction of conditional share capital for shareholder options and warrants, the implementation of a capital band through December 31, 2030, and increasing the maximum Board of Directors size from five to seven. The company also announced the appointment of Carl von Halem as Interim CFO and Christoph Erkel, Ph.D., as Chief Scientific Officer. Additionally, the company initiated cell line development for its BiTAC-TCE technology platform. Veraxa Biotech AG is a biotechnology company developing next-generation cancer therapeutics.

Veraxa Biotech AG announced on June 18, 2026, the generation of new in vitro proof-of-concept proof of concept data validating its BiTAC-ADC technology platform. The company is seeking partnering opportunities through discussions at the BIO International Convention 2026. Veraxa Biotech AG operates in the biotechnology industry and develops BiTAC-ADC technology.